This series started with the Yale secret shopper study — 45 of 49 telehealth sites prescribing GLP-1 medications, two-thirds with zero clinician interaction. That was the opening chapter, not the whole story. Here's what's actually happened in the weeks since, and what's still unresolved.
What's changed since July
- Increased scrutiny on intake design. Coverage of the study has pushed the "AI triage vs. real clinical review" question into the open in a way it wasn't before — platforms are facing more direct questions about where automation ends and a clinician's judgment begins.
- Renewed attention on state licensing enforcement. The study landed in the same window as ongoing shifts in interstate licensure compacts and DEA telemedicine flexibility deadlines — regulatory conversations that were already active got a sharper, more public example to point to.
- More visible "verified provider" positioning from platforms with real oversight. Companies with defensible clinical processes have leaned into that as a differentiator rather than staying quiet, which is a reasonable market response even if it's also, plainly, marketing.
What hasn't changed — yet
No new federal telehealth prescribing standard has been enacted specifically in response to the study. Studies like this tend to accelerate conversations that were already underway rather than create entirely new ones on their own, and that appears to be the pattern here so far.
The underlying business incentive hasn't shifted. A platform that converts more signups into prescriptions still makes more money doing that than it does investing in follow-up infrastructure. Studies change the conversation; they don't automatically change the math.
The realistic timeline
Regulatory and industry responses to studies like this typically play out over quarters, not weeks — public comment periods, licensing board reviews, and any legislative response all move slower than a single news cycle. If you're looking for the actual policy outcome, checking back in six to twelve months will tell you more than checking back next week.
What this series covered, if you're catching up
- How to verify a provider isn't cutting corners on oversight, and how to spot an outright fraudulent platform
- What's actually covered by Medicare, employer plans, and cash-pay pricing — and the real dollar gap between telehealth, urgent care, and the ER
- How AI triage, data privacy practices, and state licensing rules shape the care you actually receive
- Specific verticals — mental health, dermatology, women's health, TRT and GLP-1 combination therapy — and what translates well to virtual care versus what doesn't
A study changes what people ask. It takes longer to change what platforms have to answer for.
What to actually do with all of this
None of the coverage above should function as a reason to avoid telehealth — for the majority of conditions and the majority of platforms, it remains a genuinely useful, often better option than the alternatives. The practical takeaway across this whole series is narrower and more useful than "be careful": ask specific questions about clinical oversight, verify licensing and pharmacy accreditation before you pay, and choose platforms that treat follow-up care as core to the product rather than optional.
Providers that held up across this review series
Across this series, the providers below were referenced most consistently for maintaining documented oversight, follow-up structure, and licensing transparency.
Consistently referenced across this series
Sesame appeared across more articles in this series than any other provider, for brand-name prescribing, broad licensure, transparent pricing, and documented follow-up structure.
See Sesame Care's full range of programs → Paid linkEden's direct intake pathway and documented follow-up cadence held up as a consistent example of what real oversight looks like for compounded medication.
See Eden Health's program → Paid linkThe bottom line
The Yale study was a snapshot, not a verdict on telehealth as a model. What it revealed — and what this series has tried to unpack — is that "telehealth" isn't one thing with one standard of care. It's a wide range of businesses operating under the same word, some of them excellent and some of them cutting every corner they can get away with. The tools for telling them apart aren't complicated. They just take five extra minutes most people skip.